09:58 AM EST - Cardiol Therapeutics Inc. : Today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association. Cardiol Therapeutics Inc.
shares T.CRDL are trading down $0.02 at $1.80.
